Novel reversible XPO1 inhibitor demonstrates potent anticancer activity

Our newest research has been published in Nature Communications: “Preclinical characterization of a reversible XPO1 inhibitor for cancer therapy” Exportin 1 (XPO1) is a clinically validated anticancer target that plays a key role in transporting proteins from the nucleus to the cytoplasm. Inhibiting XPO1 can trigger cancer cell death, but currently available inhibitors are often […]